Quantitation of plasma cells in bone marrow aspirates by flow cytometric analysis compared with morphologic assessment

Archives of Pathology and Laboratory Medicine

Volumn 131, Issue 6, 2007, Pages 951-955

  Smock, Kristi J ^a   Perkins, Sherrie L ^a   Bahler, David W ^a,b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BONE MARROW BIOPSY; CLINICAL ARTICLE; DIAGNOSTIC ACCURACY; FEMALE; FLOW CYTOMETRY; GOLD STANDARD; HISTOGRAM; HUMAN; HUMAN TISSUE; IMMUNOPHENOTYPING; INTERMETHOD COMPARISON; LEUKEMIA; LYMPHOMA; MALE; MORPHOLOGY; PLASMA CELL; PLASMA CELL DYSCRASIA; QUANTITATIVE DIAGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY, NEEDLE; BONE MARROW CELLS; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA; LYMPHOCYTE COUNT; LYMPHOMA; MALE; MICROSCOPY; MIDDLE AGED; PLASMA CELLS; REPRODUCIBILITY OF RESULTS;

EID: 34250189901     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Jaffe ES, Harris NL, Stein H, Vardiman JW. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001. World Health Organization Classification of Tumours.
2. Wei A, Juneja S. Bone marrow immunohistology of plasma cell neoplasms. J Clin Pathol. 2003;56:406-411.
3. Sukpanichnant S, Cousar JB, Leelasiri A, Graber SE, Greer JP, Collins RD. Diagnostic criteria and histologic grading in multiple myeloma: histologic and immunohistologic analysis of 176 cases with clinical correlation. Hum Pathol. 1994;25:308-318.
4. Chilosi M, Adami F, Lestani M, et al. CD138/syndecan-1: a useful immunohistochemical marker of normal and neoplastic plasma cells on routine trephine bone marrow biopsies. Mod Pathol. 1999;12:1101-1106.
5. O'Connell FP, Pinkus JL, Pinkus GS. CD138 (syndecan-1), a plasma cell marker immunohistochemical profile in hematopoietic and nonhematopoietic neoplasms. Am J Clin Pathol. 2004;121:254-263.
6. Nowakowski GS, Witzig TE, Dingli D, et al. Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma. Blood. 2005;106:2276-2279.
7. van Zaanen HC, Vet RJ, de Jong CM, von dem Borne AE, van Oers MH. A simple and sensitive method tor determining plasma cell isotype and monoclonality in bone marrow using flowcytometry. Br J Haematol. 1995;91:55-59.
8. Rawstron AC, Davies FE, DasGupta R, et al. Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation. Blood. 2002;100:3095-3100.
9. Braylan RC. Impact of flow cytometry on the diagnosis and characterization of lymphomas, chronic lymphoproliferative disorders and plasma cell neoplasias. Cytometry A. 2004;58:57-61.
10. Newell JO, Cessna MH, Greenwood J, Hartung L, Bahler DW. Importance of CD117 in the evaluation of acute leukemias by flow cytometry. Cytometry. 2003;52B:40-43.
11. Lin P, Owens R, Tricot G, Wilson CS. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. Am J Clin Pathol. 2004;121:482-488.
12. Witzig TE, Kimlinger T, Stenson M, Therneau T. Syndecan-1 expression on malignant cells from the blood and marrow of patients with plasma cell proliferative disorders and B-cell chronic lymphocytic leukemia. Leuk Lymphoma. 1998;31:167-175.
13. Bayer-Garner IB, Sanderson RD, Dhodapkar MV, Owens RB, Wilson CS. Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: shed syndecan-1 accumulates in fibrotic regions. Mod Pathol. 2001;14: 1052-1058.
14. Rawstron AC, Owen KG, Davies FE, et al. Circulating plasma cells in multiple myeloma: characterization and correlation with disease stage. Br J Haematol. 1997;97:46-55.
15. Braylan RC, Orfao A, Borowitz MJ, Davis BH. Optimal number of reagents required to evaluate hematolymphoid neoplasias: results ot an international consensus meeting. Cytometry. 2001;46:23-27.